Whats interesting about this is that Biotron is the Smaallest and the Least valued in this Sector of HCV Development STAGES...
Protease inhibitors Company Phase
Boceprevir Merck Approved
Telaprevir Vertex / Tibotec Approved
BI 201335 Boehringer Ingelheim Pharma Phase III
TMC435 Tibotec Phase III
Vaniprevir (MK-7009) Merck Phase II
RG7227 (Danoprevir) InterMune / Genentech Phase II
ABT-450 Abbott / Enanta Phase II
ACH-1625 Achillion Phase II
BIT225 Biotron Phase II
BMS 650032 Bristol-Myers Squibb Phase II
GS-9256 Gilead Phase II
MK-5172 Merck Phase II
biolinerx shares pop on hep c pact, page-5
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
-0.002(7.14%) |
Mkt cap ! $23.46M | |||
| Open | High | Low | Value | Volume |
| 2.7¢ | 2.7¢ | 2.6¢ | $51.84K | 1.992M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 198646 | 2.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.6¢ | 199924 | 1 |
View Market Depth
| Last trade - 15.36pm 30/08/2024 (20 minute delay) ? |
| BIT (ASX) Chart |